All data are based on the daily closing price as of April 1, 2025
l
Lumosa Therapeutics
6535.TWO
5.21 USD
-0.15
-2.80%
Overview
Last close
5.21 usd
Market cap
859.65M usd
52 week high
12.06 usd
52 week low
1.82 usd
Target price
6.93 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
746.263
Price/Book Value
15.7264
Enterprise Value
865.04M usd
EV/Revenue
733.4959
EV/EBITDA
N/A
Key financials
Revenue TTM
1.18M usd
Gross Profit TTM
533524.1 usd
EBITDA TTM
-10.63M usd
Earnings per Share
-0.08 usd
Dividend
N/A usd
Total assets
49.09M usd
Net debt
-8.59M usd
About
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT " 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.